Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Plasma cell 2Myeloid 2Lymphoid 2

Conditions

Multiple Myeloma 2Recurrence 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Dexamethasone 116Bortezomib 63Cyclophosphamide 51Lenalidomide 49Calcium Dobesilate 46Melphalan 37pomalidomide 36fludarabine 28Filgrastim 26fludarabine phosphate 23carfilzomib 22daratumumab 21Whole-Body Irradiation 17Granulocyte Colony-Stimulating Factor 17Mycophenolic Acid 15Antilymphocyte Serum 15dexamethasone acetate 14Tacrolimus 14Thalidomide 13Cyclosporine 13Busulfan 13Radiotherapy 12Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Stem Cell Transplantation 9Rituximab 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Methylprednisolone Acetate × Plasma cell × Clear all
NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡